Although the necessity for LBs in the detection of T790M mutations was diminished by the introduction of osimertinib, a more comprehensive frame of reference seems appropriate, since only 12% to 45% of NSCLC patients present with EGFR mutations, depending on geography, histology, and smoking status [152,153]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.